CHST12

Across TCGA pan-cancer cohorts, CHST12 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHST12 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CHST12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CHST12 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where CHST12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.882	0.478	.005	21	view →
LUAD	DFS	Median	All	0.475	0.734	.011	6	view →
PDAC	DFS	Quartile	II,III,IV	0.615	0.216	.011	5	view →
UCEC	DFS	Median	All	0.804	1.000	.039	4	view →
LSCC	OS	Tertile	II,III,IV	0.522	0.881	.020	4	view →
HNSC	DFS	Median	All	0.904	1.000	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHST12–CCRCC (DFS)

Open the CCRCC breakdown →